急性胰腺炎液体复苏随机对照试验中PAN-PROMISE症状量表的评估
本研究为WATERFALL试验的辅助研究,纳入248例急性胰腺炎患者,在基线、24、48、72小时评估PAN-PROMISE症状评分。该评分与严重程度、坏死、持续性器官衰竭、ICU入住及住院时间延长在所有时间点均显著相关(P<0.05),基线评分对严重程度和坏死的AUC略高于BISAP但差异无统计学意义。
要点
- PAN-PROMISE评分与急性胰腺炎严重程度、坏死、持续性器官衰竭、ICU入住及住院时间延长在所有时间点显著相关(P<0.05)。
- 基线PAN-PROMISE评分对严重程度和坏死的AUC略高于基线BISAP,但差异无统计学意义。
- PAN-PROMISE评分在随机对照试验中与已确立的急性胰腺炎终点相关,可作为未来临床试验的终点指标。
核心结论
- 在随机对照试验背景下,以患者为中心的PAN-PROMISE评分已与已确立的急性胰腺炎结局指标进行验证,并可作为未来临床试验的终点指标。
研究设计与样本
- 本研究为WATERFALL试验的辅助研究,共纳入248例来自WATERFALL试验的患者。
- PAN-PROMISE评分在基线、24、48和72小时进行评估。
主要发现
- PAN-PROMISE与严重程度、坏死、持续性器官衰竭、ICU入住及住院时间延长在所有时间点均呈统计学显著关联(P<0.05)。
- 较高的PAN-PROMISE评分与感染性胰腺坏死在24、48和72小时显著相关,与死亡在基线和24小时显著相关。
- 基线PAN-PROMISE评分对严重程度和坏死的受试者工作特征曲线下面积略高于基线BISAP,但结果无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The PAN-PROMISE symptom score is the first patient-reported outcome in acute pancreatitis (AP). It was developed and validated in a prospective cohort of patients to be used as an endpoint in research. The aim of this study was to assess the performance of the score in a large randomized controlled trial and its association with well-established AP endpoints. METHODS: This is an ancillary study of the WATERFALL trial, where PAN-PROMISE was evaluated at baseline, 24, 48, and 72 hours. The study examined the association between PAN-PROMISE with established endpoints in AP: severity, pancreatic and/or peripancreatic fat necrosis (necrosis), infected necrosis, intensive care unit admission, persistent organ failure, prolonged hospital stay, and mortality. Areas under the receiver operating characteristic curve were calculated and used to compare baseline PAN-PROMISE and baseline Bedside Index for Severity in AP (BISAP) for the prediction of these endpoints. RESULTS: In total, 248 patients from the WATERFALL trial were included. A statistically significant association was found between PAN-PROMISE and severity, necrosis, persistent organ failure, intensive care unit admission, and prolonged hospital stay at all checkpoints ( P < 0.05). Higher scores were also significantly associated with infected pancreatic necrosis at 24, 48, and 72 hours and death at baseline and 24 hours. The PAN-PROMISE baseline score had slightly higher areas under the receiver operating characteristic curve than BISAP for severity and necrosis, but the results were not statistically significant. DISCUSSION: In the context of a randomized controlled trial, the PAN-PROMISE score, a patient-centered measure, has been validated with established AP outcomes and as an endpoint for future clinical trials.
引用
- Guilabert L, Cárdenas-Jaén K, Buxbaum JL, et al. Evaluation of the PAN-PROMISE Symptom Scale in a Randomized Controlled Trial of Fluid Resuscitation in Acute Pancreatitis. Am J Gastroenterol. 2025. PMID: 40471836. doi:10.14309/ajg.0000000000003570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。